History and the present state of hypolipidaemic therapy

Česká verze

Authors: R. Bartas ¹; J. Kolář ²
Authors place of work: Lékárna Aqua, Karviná ¹; Veterinární a farmaceutická univerzita Brno, Farmaceutická fakulta, Ústav aplikované farmacie ²
Published in the journal: Čes. slov. Farm., 2008; 57, 208-214
Category: Přehledy a odborná sdělení

Summary

History of hypolipidaemic therapy is closely connected with the development of the knowledge of atherosclerosis pathogenesis and lipid metabolism. Isolation of statins (and also their synthesis) and their subsequent implementation in practice were a decisive discovery that affected contemporary cardiology. Statins rank among the most widely utilized drugs and some of them belong to very commercially successful preparations. There are very few therapeutic groups the therapeutic contribution of which is documented so well. Several prospective drugs with different mechanisms of effect are being developed at present.

Keywords:
hypolipidaemics –⁠ atherosclerosis –⁠ ischemic heart disease –⁠ statins

Zdroje

1. Pater, C.: Curr. Control. Trials Cardiovasc. Med., 2001; 2, 24–37.

2. Steinberg, D.: J. Lipid Res., 2004; 45, 1583–1593.

3. Steinberg, D.: J. Lipid Res., 2006; 47, 1–14.

4. Steinberg, D.: J. Lipid Res., 2005; 46, 179–190.

5. Steinberg, D.: J. Lipid Res., 2005; 46, 2037–2051.

6. All Nobel Laureates in Medicine [on line]., [cit. 2008-05-15]. Dostupný z www: <http://nobelprize.org/nobel_ prizes/medicine/laureates/index.html>

7. Endo, A.: J. Lipid Res., 1992; 33, 1569–1582.

8. Bultas, J., Karetová, D.: Pace News, 2004; 3, 1–4.

9. Steinberg, D.: J. Lipid Res., 2006; 47, 1339–1351.

10. Hlinomaz, O., Groch, L.: Interv. Akut. Kardiol., 2003; 2, 123–136.

11. Pfizer ukončil vývoj léku na cholesterol. [on line]., [cit. 2008-04-15]. Dostupný z www:<http://www.medical-tribune.cz/aktualita/1942>

12. Sobolová, L.: Klin. Farmakol. Farm., 2005; 19, 22–26.

13. Češka, R. , Doležal, T.: Farmakoterapie 2006; 2, 183–188.

14. Štulc, T. Ezetimib: zklamání ze studie ENHANCE. Lékařské listy 2008; 10, 30–31.

15. --: Farmakoterapie 2007; 4, 367.

16. Pikto-Pietkiewicz, W., Wołkowska, K., Pasierski, T.: Pharmacological Reports 2005; 57 (Suppl.), 10–19.

17. Scharnagl, H. et al.: Atherosclerosis 2000; 153, 69–80.

18. Locker, P. K. et al.: Clinical Pharmacology & Therapeutics 1995; 57, 73–88.

19. Tardif, J. et al.: JAMA, 2007; 297, 1675–1682.

20. Bultas, J.: Farmakoterapie, 2006; 2, 151–153.

21. UPDATE 2-US FDA tells Takeda to stop some TAK-475 trials. [on line]., [cit. 2008-04-15]. Dostupný z www: <http://www.reuters.com/article/governmentFilingsNews/idUST17428120071029>

22. Češka, R.: Kap Kardiol., 2006; 8, 22–25.

23. Bultas, J.: Interní medicína pro praxi, 2006; 7/8, 314–322.

24. Berger, A., Jones J. H. P., Abumweis, S., S.: Lipids Health Dis., 2004; 3, 1–19.